CN103524480B - A kind of preparation method of duloxetine hydrochloride - Google Patents
A kind of preparation method of duloxetine hydrochloride Download PDFInfo
- Publication number
- CN103524480B CN103524480B CN201310493911.8A CN201310493911A CN103524480B CN 103524480 B CN103524480 B CN 103524480B CN 201310493911 A CN201310493911 A CN 201310493911A CN 103524480 B CN103524480 B CN 103524480B
- Authority
- CN
- China
- Prior art keywords
- compound
- duloxetine
- hydrochloride
- temperature
- sodium hydroxide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960002496 duloxetine hydrochloride Drugs 0.000 title claims abstract description 21
- JFTURWWGPMTABQ-UHFFFAOYSA-N n,n-dimethyl-3-naphthalen-1-yloxy-3-thiophen-2-ylpropan-1-amine Chemical compound C=1C=CC2=CC=CC=C2C=1OC(CCN(C)C)C1=CC=CS1 JFTURWWGPMTABQ-UHFFFAOYSA-N 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims abstract description 50
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 28
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims abstract description 26
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims abstract description 26
- 238000006243 chemical reaction Methods 0.000 claims abstract description 18
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 claims abstract description 18
- 150000001875 compounds Chemical class 0.000 claims abstract description 17
- 239000007787 solid Substances 0.000 claims abstract description 17
- 235000019270 ammonium chloride Nutrition 0.000 claims abstract description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 36
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 36
- 238000003756 stirring Methods 0.000 claims description 21
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 18
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 15
- 238000001035 drying Methods 0.000 claims description 10
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 238000000605 extraction Methods 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 239000011734 sodium Substances 0.000 claims description 5
- 238000010792 warming Methods 0.000 claims description 5
- 230000006837 decompression Effects 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 2
- 238000010025 steaming Methods 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract description 12
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 abstract description 7
- WYJOVVXUZNRJQY-UHFFFAOYSA-N 2-Acetylthiophene Chemical compound CC(=O)C1=CC=CS1 WYJOVVXUZNRJQY-UHFFFAOYSA-N 0.000 abstract description 6
- 229960002866 duloxetine Drugs 0.000 abstract description 6
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- 230000035484 reaction time Effects 0.000 abstract description 4
- 238000002425 crystallisation Methods 0.000 abstract description 3
- 230000008025 crystallization Effects 0.000 abstract description 3
- 239000002994 raw material Substances 0.000 abstract description 3
- 238000010189 synthetic method Methods 0.000 abstract description 3
- 238000001953 recrystallisation Methods 0.000 abstract description 2
- 238000000034 method Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000000935 antidepressant agent Substances 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 230000001519 thymoleptic effect Effects 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 229940029644 cymbalta Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- PYNUOAIJIQGACY-UHFFFAOYSA-N propylazanium;chloride Chemical compound Cl.CCCN PYNUOAIJIQGACY-UHFFFAOYSA-N 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a kind of preparation method of duloxetine hydrochloride, compound III is instilled the obtained compound ii of reaction in sodium hydroxide by it, compound ii adds solid ammonium chloride in batches and obtains duloxetine and become hydrochloride, first wash with cold diethyl ether, crystallization is carried out again with acetone, thus the obtained duloxetine hydrochloride that purity is high, yield is high.Compared with prior art this substantially reduces the reaction times, within 18 ~ 70 hours by document, foreshorten to 2 ~ 4 hours; In addition utilize duloxetine of the present invention to become hydrochloride more simple and easy to do, and productive rate is higher; Be first wash with cold diethyl ether before carrying out crystallization with acetone, can easierly make duloxetine hydrochloride be precipitated out like this, and purity be high, again need not carry out recrystallization, avoid loss.Synthetic method of the present invention is more simple, substantially increases production efficiency, reduces production cost, can reach more than 17% from starting raw material 2-acetyl thiophene synthetic hydrochloric acid duloxetine overall yield.
Description
Technical field
The present invention relates to a kind of preparation method of duloxetine hydrochloride, belong to organic chemistry and medicinal chemistry art.
Technical background
Duloxetine hydrochloride (duloxetinehydrochloride, formula I), chemistry (+)-(S)-N-methyl-3-(1-naphthyloxy)-3-(2-thienyl by name) propylamin hydrochloride is the thymoleptic that a kind of re-uptake to serotonin and norepinephrine has double inhibition effect.
This Eli-Lilly company of Yao Shi U.S., after fluoxetine Patent expiry, the another new drug of release, commodity are called Cymbalta.In September, 2002, through U.S. FDA approval treatment major depression, uses its hydrochloride clinically.In September, 2004, U.S. FDA have approved to supplement and is suitable for disease, is used for the treatment of diabetic external cause neuralgia.Be clinical preferred thymoleptic now, therefore have great scientific research and economic worth to its research, especially its patent protection expired in 2013, just more seems have a sense of urgency to its research.
From prior art, the synthetic route of duloxetine hydrochloride (formula I) is as follows:
But the synthetic method of prior art exists, and technique is loaded down with trivial details, long reaction time, production cost are high, product purity and the shortcoming such as yield is low, as the current synthesis from compound III to compound ii, reaction times reaches 18 ~ 70 hours, because the present invention is the improvement carried out on forefathers basis, therefore describe the place of improving at this, namely in synthetic route compound III to the synthesis of chemical compounds I, from starting raw material 2-acetyl thiophene to the synthesis of compound III mostly with reference to pertinent literature, do not repeat them here.
Summary of the invention
For the deficiencies in the prior art, the invention provides a kind of preparation method of new duloxetine hydrochloride, the generated time of duloxetine hydrochloride can be shortened, and technique is more simple.
The present invention is achieved through the following technical solutions:
A preparation method for duloxetine hydrochloride, is characterized in that comprising the steps:
A () adds the aqueous sodium hydroxide solution that concentration is 5%-20% in reaction vessel, control temperature 0 DEG C ~ 30 DEG C, drip the DMSO solution of compound III, the mol ratio of solid sodium hydroxide and compound III is 3 ~ 5:1, drips off and is warming up to 40 DEG C ~ 70 DEG C reactions 2 ~ 6 hours, frozen water is poured under stirring, adjust pH to 4.5 ~ 5.5 with acetic acid, with n-hexane extraction twice, water layer adjusts pH to 11-12 with 50% sodium hydroxide again, be extracted with ethyl acetate three times, anhydrous Na
2sO
4after drying, control bath temperature and be no more than 48 DEG C of evaporated under reduced pressure ethyl acetate, obtain light brown liquid, i.e. compound ii.
Preferably, compound III drip into naoh concentration be 15%.
Preferably, the mol ratio of solid sodium hydroxide and compound III is 4:1.
Preferably, when compound III drips, described temperature is 20 DEG C.
Preferably, described temperature of reaction is 55 DEG C.
Preferably, acetic acid adjusts pH to 5.
Preferably, the bath temperature of ethyl acetate is steamed in decompression is 45 DEG C.
B (), in reaction vessel, adds compound ii and methyl alcohol, stir after dissolving completely, room temperature lower point 2 ~ 5 batches, often criticizes interval and adds solid ammonium chloride in 5 ~ 25 minutes, and the mol ratio of compound ii and ammonium chloride is 1:1 ~ 1.2, stirred at ambient temperature reaction 1 ~ 3 hour, control bath temperature and be no more than 48 DEG C of evaporated under reduced pressure methyl alcohol, add proper amount of acetone with after appropriate cold ether, stir 1 hour under ice bath, filter, with proper amount of acetone washing, drying obtains compound as white solid I, i.e. duloxetine hydrochloride.
Preferably, divide 3 batches and add ammonium chloride, often criticize interval 15 minutes.
Preferably, the mol ratio of compound ii and ammonium chloride is 1:1.05.
Preferably, the bath temperature of methyl alcohol is steamed in decompression is 40 DEG C.
Its synthetic route is as follows:
Reformed AHP compared with prior art of the present invention is as follows:
1) method of synthetic compound II provided by the invention instills in sodium hydroxide by compound III, contrary with existing method, this substantially reduces the reaction times, within 18 ~ 70 hours by document, foreshortens to 2 ~ 4 hours.
2) method of synthetic hydrochloric acid duloxetine provided by the invention, add solid ammonium chloride under room temperature to carry out duloxetine and become hydrochloride in batches, this method than existing concentrated hydrochloric acid or gas chlorination hydrogen salify all more simple, easy, and productive rate reaches more than 80%, most document is 20% ~ 60%.
3) provided by the inventionly obtain pure duloxetine hydrochloride Solid Method, be first wash with cold diethyl ether before carrying out crystallization with acetone, can easierly make duloxetine hydrochloride be precipitated out like this, and purity be high, again need not carry out recrystallization, avoid loss.
4) duloxetine hydrochloride synthetic method of the present invention is more simple, substantially increase production efficiency, reduce production cost, can more than 17% be reached from starting raw material 2-acetyl thiophene synthetic hydrochloric acid duloxetine overall yield, most document is less than 12%, have minority productive rate to reach more than 20%, but be through test of many times checking all do not reach document description yield.
Embodiment
The present invention is described in detail to use specific embodiment below, but be not limited thereto.
embodiment 1:
A the NaOH aqueous solution of prepare 15% is taken 147g and joins in reaction by (), under vigorous stirring, control temperature about 20 DEG C drips the DMSO solution 450mL being dissolved with 55.5g compound III.Be warming up to 55 DEG C after dripping off, react and after 3 hours, 550g frozen water is poured into wherein, stir after half an hour and adjust pH to 5 with acetic acid, with n-hexane extraction twice.Waterlayer control temperature is no more than 30 DEG C and adjusts pH to 11 ~ 12 with 50% sodium hydroxide, is extracted with ethyl acetate 400mL × 3 time, anhydrous Na
2sO
4after drying, control water-bath 45 DEG C of evaporated under reduced pressure ethyl acetate, obtain light brown liquid 39.5g.
B () adds compound ii and the 240mL methyl alcohol of 32.5g in reaction flask, after stirring at room temperature is dissolved completely, add solid ammonium chloride 6.5g, then continue stirring under room temperature 2 hours at interval of 15 minutes points 3 batches.Control bath temperature about 41 DEG C evaporated under reduced pressure methyl alcohol, wash once with cold diethyl ether, then add 220mL acetone, stir 1 hour under ice bath, filter, with proper amount of acetone and washed with ether twice, drying obtains 32.1g white solid, i.e. duloxetine hydrochloride, yield 87.9%, HPLC purity is 99.8%.
embodiment 2:
A the NaOH aqueous solution of prepare 5% is taken 147g and joins in reaction by (), under vigorous stirring, control temperature 30 DEG C of droppings are dissolved with the DMSO solution 450mL of 55.5g compound III.Be warming up to 70 DEG C after dripping off, react and after 2 hours, 550g frozen water is poured into wherein, stir after half an hour and adjust pH to 4.5 with acetic acid, with n-hexane extraction twice.Waterlayer control temperature is no more than 30 DEG C and adjusts pH to 11 ~ 12 with 50% sodium hydroxide, is extracted with ethyl acetate 400mL × 3 time, anhydrous Na
2sO
4after drying, control water-bath 40 DEG C of evaporated under reduced pressure ethyl acetate, obtain light brown liquid, 38g.
B () adds compound ii and the 240mL methyl alcohol of 32.5g in reaction flask, after stirring at room temperature is dissolved completely, add solid ammonium chloride 6.5g, then continue stirring under room temperature 1 hour at interval of 5 minutes points 5 batches.Control bath temperature about 40 DEG C evaporated under reduced pressure methyl alcohol, wash once with cold diethyl ether, then add 220mL acetone, stir 1 hour under ice bath, filter, with proper amount of acetone and washed with ether twice, drying obtains 30g white solid, i.e. duloxetine hydrochloride, yield 82.2%, HPLC purity is 99.69%.
embodiment 3:
A the NaOH aqueous solution of prepare 20% is taken 147g and joins in reaction by (), under vigorous stirring, control temperature 30 DEG C of droppings are dissolved with the DMSO solution 450mL of 55.5g compound III.Be warming up to 40 DEG C after dripping off, react and after 6 hours, 550g frozen water is poured into wherein, stir after half an hour and adjust pH to 5.5 with acetic acid, with n-hexane extraction twice.Waterlayer control temperature is no more than 30 DEG C and adjusts pH to 11 ~ 12 with 50% sodium hydroxide, is extracted with ethyl acetate 400mL × 3 time, anhydrous Na
2sO
4after drying, control water-bath 40 DEG C of evaporated under reduced pressure ethyl acetate, obtain light brown liquid, 39.4g.
B () adds compound ii and the 240mL methyl alcohol of 32.5g in reaction flask, after stirring at room temperature is dissolved completely, add solid ammonium chloride 6.5g, then continue stirring under room temperature 3 hours at interval of 20 minutes points 2 batches.Control bath temperature about 40 DEG C evaporated under reduced pressure methyl alcohol, wash once with cold diethyl ether, then add 220mL acetone, stir 1 hour under ice bath, filter, with proper amount of acetone and washed with ether twice, drying obtains 30.7g white solid, i.e. duloxetine hydrochloride, yield 84.1%, HPLC purity is 99.7%.
Claims (1)
1. a preparation method for duloxetine hydrochloride, is characterized in that comprising the steps:
A () adds the aqueous sodium hydroxide solution that concentration is 5%-20% in reaction vessel, control temperature 0 DEG C ~ 30 DEG C, drip the DMSO solution of compound III, the mol ratio of solid sodium hydroxide and compound III is 3 ~ 5:1, drips off and is warming up to 40 DEG C ~ 70 DEG C reactions 2 ~ 6 hours, frozen water is poured under stirring, adjust pH to 4.5 ~ 5.5 with acetic acid, with n-hexane extraction twice, water layer adjusts pH to 11-12 with 50% sodium hydroxide again, be extracted with ethyl acetate three times, anhydrous Na
2sO
4after drying, control bath temperature and be no more than 48 DEG C of evaporated under reduced pressure ethyl acetate, obtain light brown liquid, i.e. compound ii; The naoh concentration starting to join reaction vessel is 15%; The mol ratio of described solid sodium hydroxide and compound III is 4:1; The dropping temperature of described compound III controls at 20 DEG C; Dripping the temperature of reaction after compound III is 55 DEG C; Bath temperature during described decompression steaming ethyl acetate is 45 DEG C,
B (), in reaction vessel, adds compound ii and methyl alcohol, stir after dissolving completely, room temperature lower point 2 ~ 5 batches, often criticizes interval and adds solid ammonium chloride in 5 ~ 25 minutes, and the mol ratio of compound ii and ammonium chloride is 1:1 ~ 1.2, stirred at ambient temperature reaction 1 ~ 3 hour, control bath temperature and be no more than 48 DEG C of evaporated under reduced pressure methyl alcohol, add proper amount of acetone with after appropriate cold ether, stir 1 hour under ice bath, filter, with proper amount of acetone washing, drying obtains compound as white solid I, i.e. duloxetine hydrochloride; Divide 3 batches and add ammonium chloride, often criticize interval 15 minutes; The mol ratio of compound ii and ammonium chloride is 1:1.05; The bath temperature that methyl alcohol is steamed in decompression is 40 DEG C;
Its synthetic route is as follows:
。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310493911.8A CN103524480B (en) | 2013-10-21 | 2013-10-21 | A kind of preparation method of duloxetine hydrochloride |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310493911.8A CN103524480B (en) | 2013-10-21 | 2013-10-21 | A kind of preparation method of duloxetine hydrochloride |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103524480A CN103524480A (en) | 2014-01-22 |
| CN103524480B true CN103524480B (en) | 2016-04-20 |
Family
ID=49926881
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310493911.8A Active CN103524480B (en) | 2013-10-21 | 2013-10-21 | A kind of preparation method of duloxetine hydrochloride |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103524480B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115286613B (en) * | 2022-10-08 | 2023-01-31 | 潍坊市海欣药业有限公司 | Preparation method of duloxetine hydrochloride |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5023269A (en) * | 1986-12-22 | 1991-06-11 | Eli Lilly And Company | 3-aryloxy-3-substituted propanamines |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007119116A2 (en) * | 2005-12-12 | 2007-10-25 | Medichem, S.A. | Improved synthesis and preparations of duloxetine salts |
-
2013
- 2013-10-21 CN CN201310493911.8A patent/CN103524480B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5023269A (en) * | 1986-12-22 | 1991-06-11 | Eli Lilly And Company | 3-aryloxy-3-substituted propanamines |
Non-Patent Citations (1)
| Title |
|---|
| 盐酸度洛西汀的合成工艺改进研究;朱占群 等;《中国新药杂志》;20091231;第18卷(第5期);第447-450页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103524480A (en) | 2014-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101607955B (en) | Preparation method for low-residue lipoic acid | |
| CN103524480B (en) | A kind of preparation method of duloxetine hydrochloride | |
| CN104892444B (en) | A kind of method of synthesizing D-p-hydroxyphenylglycine methyl ester | |
| CN105330560A (en) | Enzalutamide intermediate preparation method | |
| CN105152947A (en) | Preparation method of 2-amino-3,5-dibromobenzaldehyde | |
| CN102249962B (en) | Preparation method of 1,1-disulfur-1-olefin | |
| CN103709209A (en) | Isopropyl-beta-D-thiogalactoside preparation method | |
| CN103965197B (en) | Allopurinol crystal preparation | |
| CN104188980B (en) | O-(morpholinyl) ethyl derivatives of cleistanone Cleistanone, preparation method and use thereof | |
| CN102180864B (en) | Preparation method of strontium ranelate | |
| CN104829587B (en) | The preparation of duloxetine hydrochloride | |
| CN103508998A (en) | Method for preparing intermediate of duloxetine hydrochloride | |
| CN104761567A (en) | Clopidogrel hydrogen sulfate, and intermediate and preparation method thereof | |
| CN105777852A (en) | Deflazacort synthetic method | |
| CN101805354B (en) | Preparation method of I type clopidogrel hydrogen sulfate | |
| CN103922366B (en) | A kind of Delan of utilization produces the method for mother liquor extracting sulfuric acid sodium | |
| CN105906589A (en) | Preparation method of furosemide | |
| CN103755727B (en) | Preparation method of brinzolamide intermediate | |
| CN103694285B (en) | A kind of preparation method of isopropyl-β-D-thiogalactoside(IPTG) | |
| CN104163811A (en) | New method for preparation of duloxetine hydrochloride | |
| CN103709210A (en) | Isopropyl-beta-D-thiogalactoside preparation technology | |
| CN103694286B (en) | Prepare the method for isopropyl-β-D-thiogalactoside(IPTG) | |
| CN113912665B (en) | Method for synthesizing 3-methoxy-18 beta-glycyrrhetinic acid | |
| CN104513225A (en) | Preparation method of 2-thiopheneacetonitrile | |
| CN103360365A (en) | New preparation process of medicinal raw material duloxetine hydrochloride of antidepressant drug |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |